Immobilized Human ACE2, Fc Tag (Cat. No. AC2-H5257) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52H7) with a linear range of 0.2-6 ng/mL (QC tested).
Immobilized Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) at 1 μg/mL (100 μL/well) can bind SARS-CoV-2 S protein, His Tag, Super stable trimer (Cat. No. SPN-C52) with a linear range of 0.2-3 ng/mL (Routinely tested).
The newly identified 2019 novel coronavirus (SARS-CoV-2) has posed a serious threat to human health. Currently, there is no specific treatment for COVID-19. It is urgent to develop the SARS-CoV-2 inhibitors, for example vaccines and therapeutic antibodies and small molecular compounds against COVID-19.
Important Licensing Information: This product may be covered by Limited Use Label License(s). By use of this product, you accept the terms and conditions of all applicable Limited Use Label License(s).
Limited Use Label License No. 18: Engineered Coronavirus Spike Proteins
This product and its use is the subject of U.S. Provisional Patent Application No. 63/032,502 and sold under a license from The University of Texas at Austin. Rights to use this product are limited to research and clinical diagnostics, and expressly exclude the right to use in human therapeutics, vaccines, and any use involving the administration of this product to humans.